Q2 2025 Abcellera Biologics Inc Earnings Call Transcript
Key Points
- AbCellera Biologics Inc (ABCL) achieved a major milestone by receiving Health Canada authorization to initiate its first two clinical trials for ABCL635 and ABCL575.
- The company has begun dosing in its Phase 1 clinical trial for ABCL635, marking its transition from a platform company to a clinical-stage biotech.
- AbCellera Biologics Inc (ABCL) ended the quarter with approximately $750 million in available liquidity, positioning it well to execute its strategy.
- The company advanced ABCL688 into IND-enabling studies, adding a third program to its pipeline.
- Revenue for the quarter was approximately $17 million, a significant increase from $7 million in the same quarter of 2024.
- AbCellera Biologics Inc (ABCL) reported a net loss of roughly $35 million for the quarter, compared to a loss of $37 million in the same quarter last year.
- Research and development expenses for the quarter were approximately $39 million, reflecting ongoing investment in internal and co-development programs.
- The company expects research fee revenue to continue trending lower as it focuses more on internal and co-development programs.
- The licensing revenue of $10 million was a one-off payment related to the acquisition of Trianni, not expected to recur.
- The company is still in early stages for its clinical trials, with initial safety and efficacy data for ABCL635 expected only in mid-2026.
Good afternoon, and welcome to AbCellera's second quarter 2025 business update conference call. My name is Jason, and I'll facilitate the audio portion of today's interactive broadcast. At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. You may begin.
Thank you. Hello, everyone. Thank you for joining us for AbCellera's 2025 second quarter earnings call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Dr. Carl Hansen, AbCellera's President and CEO; and Andrew Booth, AbCellera's Chief Financial Officer, are also on the call.
During today's call, we anticipate making projections and forward-looking statements based on our current expectations and following the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Our actual results may differ materially due to several factors outlined in our latest Form 10-K and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
